Premium
ACS Treatment Continues to Improve: But Price Matters
Author(s) -
Heuser Richard R.
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26790
Subject(s) - prasugrel , ticagrelor , medicine , platelet inhibition , p2y12 , platelet aggregation inhibitor , key (lock) , intensive care medicine , clopidogrel , platelet , platelet aggregation , myocardial infarction , ecology , biology
Key Points Over 90% of patients achieve adequate levels of platelet inhibition with both Prasugrel and Ticagrelor. The introduction of Prasugrel was met with some hesitation from physicians because of the significant increase in cost. This pharmaceutically sponsored and authored retrospective study suggests that both agents are effective.